Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 05 2017 - 8:00AM
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a
Fortress Biotech (NASDAQ:FBIO) company, today announced that James
F. Oliviero, President and Chief Executive Officer of Checkpoint,
will present a company overview at the 19th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright
& Co., LLC, on Monday, September 11, 2017 at 10:50 a.m. EDT.
The conference will be held at the Lotte New York Palace Hotel in
New York City.
A live webcast of the presentation will be
available on the Events page of the Investors & Media section
of Checkpoint’s website: www.checkpointtx.com.
About Checkpoint
TherapeuticsCheckpoint Therapeutics, Inc. (“Checkpoint”)
is a clinical-stage, immuno-oncology biopharmaceutical company
focused on the acquisition, development and commercialization of
novel, non-chemotherapy, immune-enhanced combination treatments for
patients with solid tumor cancers. Checkpoint’s broad pipeline
consists of fully-human, immuno-oncology and checkpoint inhibitor
antibodies licensed from the Dana-Farber Cancer Institute that
target programmed death-ligand 1 (“PD-L1”); glucocorticoid-induced
TNFR-related protein (“GITR”); and carbonic anhydrase IX (“CAIX”).
In addition, Checkpoint is developing three oral, small-molecule,
targeted anti-cancer agents that inhibit epidermal growth-factor
receptor (“EGFR”) mutations, the bromodomain and extra-terminal
(“BET”) protein BRD4, and poly (ADP-ribose) polymerase (“PARP”).
Checkpoint will also seek to expand its pipeline to create
additional proprietary combination therapies that leverage the
immune system and complementary mechanisms. Checkpoint is
headquartered in New York City. For more information, visit
www.checkpointtx.com. Checkpoint is a majority-controlled
subsidiary of Fortress Biotech, Inc.
About Fortress BiotechFortress
Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated
to acquiring, developing and commercializing novel pharmaceutical
and biotechnology products. Fortress develops and commercializes
products both within Fortress and through certain subsidiary
companies, also known as Fortress Companies. In addition to its
internal development programs, Fortress leverages its
biopharmaceutical business expertise and drug development
capabilities and provides funding and management services to help
the Fortress Companies achieve their goals. Fortress and the
Fortress Companies may seek licensings, acquisitions, partnerships,
joint ventures and/or public and private financings to accelerate
and provide additional funding to support their research and
development programs. For more information, visit
www.fortressbiotech.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs, and any other
statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: the risk that Checkpoint will not
be able to advance its research programs; risks related to the
timing of starting and completing of clinical trials; risks
inherent in research and development activities; risks related to
its growth strategy; its ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
uncertainties relating to preclinical and clinical testing; its
dependence on third-party suppliers; its ability to attract,
integrate, and retain key personnel; the early stage of products
under development; its need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in Checkpoint’s
public filings and reports. Checkpoint expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contacts:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Fortress Biotech Media Relations
Laura Bagby
6 Degrees
(312) 448-8098
lbagby@6degreespr.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024